3
4
of 16 quantitative traits, including metabolic, kidney-related, and electrolyte traits, suggesting a common genetic background among nephrolithiasis patients and these quantitative traits. Four novel loci are related to the metabolic pathway, while the remaining 10 loci are associated with the crystallization pathway. Our findings demonstrate the crucial roles of genetic variations in the development of nephrolithiasis.
INTRODUCTION
Nephrolithiasis is a common health problem that causes severe, acute back pain. The prevalence of nephrolithiasis is estimated to be 10-15% in men and 7% in women, and its prevalence increased by 70-85% between the 1980s and the 2000s in both the USA and Japan 1, 2 . The recurrence rate of nephrolithiasis is 30-50% within 10 years after the initial episode 3 and occasionally leads to severe complications, such as pyelonephritis or acute renal failure.
Therefore, the identification of risk factors is important for the management of nephrolithiasis.
Environmental factors, such as lifestyle, obesity 4, 5 , hypertension 6 , and diabetes 7 , are associated with an increased risk of nephrolithiasis. In addition, a positive family history increases the disease risk by 2.57-fold among the Japanese population 8 , and a twin study estimated the heritability of nephrolithiasis to be 56% 9 , suggesting a pivotal role for host genetic factors. Monogenic diseases causing hypercalciuria (CLCN5, SLC34A1, NKCC2, ROMK, and CaSR9), distal tubular acidosis (SLC4A1), hyperoxaluria (AGTXT), and cysteinuria (SLC3A1 and SLC7A9) are associated with familial nephrolithiasis syndrome 10 .
In addition, three previous GWAS in European and Japanese populations identified 6 common genetic factors on 21q22.13 (CLDN14) 11 , 5q35.3, 7p14.3, 13q14.1 12 , 1p36.12 (ALPL), and 3q21.1 (CASR) 13 . These loci were shown to be quantitative loci for ALP and serum phosphate (1p36.12), PTH and urinary Mg/Ca ratio (5q35.3 and 21q22.13), bone 6 mineral density (7p14.3 and 21q22.13), serum Ca (13q14.1 and 3q21.1) and kidney function (5q35.3), suggesting the underlying mechanism of these traits in the regulation of cations, kidney function, and mineralization. To further elucidate the genetic factors related to nephrolithiasis, we conducted GWAS using more than 13,000 Japanese cases and 190,000 control samples.
METHODS

Study participants
The characteristics of each cohort are shown in Table 1 . The diagnosis of nephrolithiasis in patients enrolled in screening 1 was confirmed by physicians, while we selected cases for screening 2 based on medical history obtained by medical coordinators in each hospital. DNA samples of 12,846 nephrolithiasis patients and 162,394 controls were obtained from BioBank Japan 14, 15 . The 28,867 controls were from four population-based cohorts, including the JPHC (Japan Public Health Center)-based prospective study 16 , the J-MICC (Japan MultiInstitutional Collaborative Cohort) study 17 , IMM (Iwate Tohoku Medical Megabank Organization) and ToMMo (Tohoku Medical Megabank Organization) 18 . A total of 573 nephrolithiasis patients and 195 healthy controls were recruited at the Nagoya City University 19 . The diagnosis of nephrolithiasis in patients from Nagoya City University (n = 573) and 7 BioBank Japan in the screening 1 (n = 6,246) was confirmed by a clinician. Cases in screening 2 (n = 4,884) and the replication (n = 1,716) were selected from samples in BioBank Japan and were based on medical history obtained by questionnaire or medical records. Genomic DNA was extracted from peripheral blood leukocytes using a standard method. All participants provided written informed consent, and the project was approved by the ethical committees at each institute.
Genotyping and imputation
The strategy of our screening is shown in Supplemental Figure 1 . In screening 1, we used clinically confirmed nephrolithiasis cases and healthy controls. In screening 2, we selected 4,884 nephrolithiasis cases and 158,772 controls from BioBank Japan based on medical records or self-reporting. In previous studies [20] [21] [22] , all 11,130 nephrolithiasis cases and 187,639 controls (screening 1 and 2) were genotyped with an Illumina HumanOmniExpressExome BeadChip or a combination of the Illumina HumanOmniExpress and HumanExome BeadChips (Table 1) . We excluded (i) samples with a call rate < 0.98, (ii) samples from closely related individuals identified by identity-by-descent analysis, (iii) sex-mismatched samples with a lack of information, and (iv) samples from non-East Asian outliers identified by principal component analysis of the studied samples and the three major reference We then applied standard quality-control criteria for variants, excluding those with (i) SNP call rate < 0.99, (ii) minor allele frequency < 1%, and (iii) Hardy-Weinberg equilibrium P value < 1.0 × 10 −6 . We prephased the genotypes with MACH 24 and imputed dosages with minimac and the 1000 Genomes Project Phase 1 (version 3) East Asian reference haplotypes 25 . Imputed SNPs with an imputation quality Rsq < 0.4 were excluded from the subsequent association analysis.
Genome-wide association analysis
We conducted a GWAS using a logistic regression model by incorporating age, sex, and the top 10 PCs as covariates. Meta-analysis of screening 1 and screening 2 was conducted by using METAL 26 . Heterogeneity between studies was examined using Cochran's Q test 27 . To estimate the genetic correlation, a bivariate LD score regression 28 was conducted using the results from the GWAS of screening 1 and screening 2 with the LD scores for the East Asian population 22 . We calculated the genomic inflation factor λGC in R. λGC adjusted to a sample size of 1,000 (λ1,000) was calculated using the following formula (1/ncases+1/ncontrols)/(1/1,000cases+1/1,000controls). A quantile-quantile plot was drawn using R.
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A Manhattan plot of the associations was constructed by plotting −log10 (P values) against chromosome position using R. We generated regional plots with LocusZoom (v. 1.3) 31 . A forest plot was drawn using R.
Replication study
Among the genome-wide significant SNPs with P < 5 × 10
from the meta-analysis of screening 1 and screening 2, we selected 17 SNPs within 14 loci by linkage disequilibrium (LD) analysis (r2 < 0.2). We genotyped 17 SNPs using 2,320 nephrolithiasis cases and 3,961
controls by the multiplex PCR-based Invader assay (Third Wave Technologies). The metaanalysis of screening 1, screening 2, and the replication was conducted using METAL in the same way as in the screening step. The threshold of heterogeneity was P < 0.05/17.
Pleiotropy analysis
The GWAS results for metabolic traits (BMI, TC, HDL-C, LDL-C, TG, BS, and HbA1c), kidney-related traits (BUN, sCr, eGFR, and UA), and electrolytes (Na, K, Cl, Ca, and P) were used in the pleiotropy analysis 22 . To assess the colocalization of causal SNPs, we conducted a conditional logistic regression analysis with conditioning of the top SNPs of the Japanese QTL GWAS. The tested SNPs were selected to be located within 1 Mb of the typing SNP.
We downloaded the NHGRI-EBI GWAS catalog (v1.0.1).
eQTL analysis
Expression data for specific tissues obtained from the GTEx Portal were used to evaluate whether the variants in the genomic loci identified in this study affect gene expression (eQTL analysis).
Subgroup analysis
We used the subjects in screening 1 for the subgroup analysis. Each subgroup was analyzed using a logistic regression model with an adjustment for sex and age. Control samples were the same as those used in screening 1. Then, comparisons between subgroups were performed using a logistic regression model with an adjustment for sex and age.
Weighted genetic risk score A total of 17 associated SNPs (P < 5.0 × 10
from the meta-analysis of screening 1 and screening 2) were used. The wGRS (weighted genetic risk score) model was established to incorporate the estimate (weight) from the meta-analysis of screening 1 and screening 2 for each of the 17 associated SNPs. The cumulative risk scores were calculated by multiplying the 11 weight of each SNP by the frequency of the risk alleles for the SNP carried by the individual, and the sum across the total number of SNPs was considered. Subsequently, the risk scores were classified into five quantiles on the basis of wGRS. P values, odds ratios, and 95%
confidence intervals were evaluated using the first quantile as the reference.
Statistical Analysis
We conducted GWAS and subgroup analysis using a logistic regression model by using plink.
Meta-analysis was conducted by using METAL. The wGRS (weighted genetic risk score) model was evaluated by Fisher's exact test by using R. Summary statistics and primary genotyping data that support the findings of this study can be found at NDBC with the accession code hum0014 (http://humandbs.biosciencedbc.jp/), after acceptance of this paper.
RESULTS
Genome wide association study of nephrolithiasis
A total of 6,246 nephrolithiasis patients and 28,867 controls (screening 1) and 4,884 nephrolithiasis cases and 158,772 controls (screening 2) were analyzed in the screening stage. All samples were genotyped using the Illumina OmniExpressExome or OmniExpress+HumanExome
BeadChip in the previous analyses ( Table 1 and Supplemental Figure 1 ) [20] [21] [22] . We excluded samples after performing a standard quality control (QC) procedure. Then, we selected 509,872 SNPs for genome-wide imputation (MAF ≥ 0.01, HWE ≥ 1x10 -6 , and call rate ≥ 0.99) and obtained imputed dosages of 6,603,247 SNPs (RSQR ≥ 0.4). We tested the association with nephrolithiasis susceptibility using a logistic regression analysis with age, sex, and the top 10 PCs as covariates. A meta-analysis of screening 1 and screening 2 indicated that 822 SNPs in 14 genomic regions including five previously reported loci showed significant association with p-value of less than 5 x10 -8 ( Figure 1 and Supplemental Table 1 ). The genomic inflation factor λ and λ1000 was 1.164 and 1.008, respectively (Supplemental Figure 2 ) 29 . The LD score regression analysis 32 of screening 1 and screening 2 revealed a genetic correlation score of 0.92, indicating that the results were consistent between the two studies.
We selected 17 SNPs in 14 genomic regions with significant associations (P < 5 x 10 -8 ) in the replication analysis based on linkage disequilibrium (LD, r 2 < 0.2) and conditioned analysis adjusted by lead SNPs in each region (Supplemental Table 2 and Supplemental Figure 3) . We substituted the top-ranked SNPs rs6667242, rs11746443, rs3798519, and rs74956940 on 1p36.12, 5q35.3, 6p12.3, and 19p13.12, respectively, for rs1697420, rs10866705, rs62405419, and rs2241358 because we could not design probes for invader assay. These 17 SNPs were analyzed using independent Japanese samples consisting of 2,289 cases and 3,817 controls 19 by a multiplex-polymerase chain reactionbased Invader assay 33 . As a result, the risk alleles were consistent, and the effect sizes were similar among the three studies (screening 1, screening 2, and replication) for 17 SNPs. A meta-analysis revealed that 16 SNPs within 14 regions including nine novel regions exceeded the genome-wide significant threshold (P < 5 x 10 -8 ) ( Table 2 ). These SNPs included: GCKR-C2orf16-ZNF512-
, and BCAS1 (20q13.2). In addition, all 6
previously identified SNPs showed a significant association (P = 0.0297 -2.76 x 10 -18
, Supplemental Table 3 ).
Nephrolithiasis is a complex disease that is regulated by many factors, such as serum/urinary cations, urate, kidney function, obesity, humoral factors, dietary factors, and hydration. To further investigate the roles of these genetic factors in the pathogenesis of nephrolithiasis, we analyzed the association of 17 variations with 16 quantitative traits in three categories, including metabolic (n = 7), kidney-related (n = 4), and electrolyte (n = 5) (Supplemental Table 4 ), which were analyzed in our previous studies 22 . Figure 6 ). We conducted a subgroup analysis using clinical information, such as recurrent stones, stone location, positive family history, and history of gout (Supplemental Figure 7) . As a result, rs35747824 and rs7277076 were significantly associated with recurrent stones, while rs35747824 and rs13006480 were associated with kidney stones and history of gout.
To evaluate the cumulative effects of genetic variants on nephrolithiasis risk, a weighted-genetic risk score (wGRS) was used. We used the 17 significant SNPs that cleared the GWAS significance threshold in the screening stage and their corresponding weights from the meta-analysis of the screening stage. Individuals were partitioned into quintile groups based on the wGRS. As a result, the highest risk group (top quantile) showed an OR of 2.130 (95% C.I.: 1.999-2.271) and 1.710 (95% C.I.:
1.422-2.059) compared with the reference group (first quantile) in the screening stage and replication stage, respectively (Supplemental Table 8 ). We also evaluated the association of these variations with the mRNA expression of nearby genes. rs1106357, rs1260326, and rs3798519 were associated with ALPL, GCKR, and TFAP2B, respectively (Supplemental Figure 8) . In addition to rs6667242, rs1106357 was also associated with nephrolithiasis, the serum ALP level, and serum P levels (Supplemental Figure 9) . These results suggested an underlying molecular mechanism whereby these variations regulate the risk of nephrolithiasis.
DISCUSSION
We found that nine novel loci were associated with the risk of nephrolithiasis in the Japanese population. To the best of our knowledge, this study is the largest genomic analysis of nephrolithiasis. Carbohydrate intake increases the absorption of calcium in the intestine and the urinary excretion of calcium via insulin secretion 34 35 . In addition, obesity is associated with higher uric acid in the serum 36 , a major component of nephrolithiasis 37 , due to increased uric acid production and decreased renal excretion. Four of nine novel risk loci were associated with higher BMI or triglycerides (2p23.3, 6p12.3, and 16q12.2) and/or higher uric acid content (2p23.3 and 17q23.2) (Figure 2 and Supplemental Figure 4 ) 38, 39 , which are well-established risk factors for nephrolithiasis 5 . FTO variations on 16q12.2 suppress the expression of IRX3 and IRX5 and subsequently increase body weight by promoting lipid storage 40 . The risk allele on 6p12.3 was associated with higher expression of TFAP2B (Supplemental Figure 8c) , and TFAP2B promotes the enlargement of adipocytes 41 . GCKR functions as a negative regulator of GCK, and the risk allele on 2p23.3 would suppress GCKR function via amino acid substitution and/or its transcriptional repression (Supplemental Figure 8b) and subsequently enhance the activity of GCK 42 , which promotes insulin secretion and triglyceride synthesis 43 and suppresses uric acid excretion 44 .
Previously, 17q23.2 was shown to be associated with hyperuricemia 22, 39, 45 , although the underlying molecular mechanism has not been elucidated. Thus, these 4 loci promote the formation of nephrolithiasis through the regulation of metabolic traits, such as obesity and uric acid production (Figure 3) . Figure 8a and 9) . ALPL hydrates and reduces pyrophosphate and acts as an inhibiter of CaOX and CaP crystallization, subsequently increasing the nephrolithiasis risk 57, 58 . rs35747824 on 16p12.3 is located within UMOD, which encodes UMOD, the most abundant protein in urine that suppresses the crystallization of Ca in urine 59 . rs1544935 on 6p21.2 is located within KCNK5, which encodes a potassium channel. Because KCNK5-knockout mice exhibit distal tubular acidosis and alkali urine that reduces the solubility of calcium phosphate products 60 , this variation regulates stone formation by regulating urine pH. Taken together, all 14 loci are associated with the regulation of either the metabolic or crystallization pathway (Figure 3) . We hope our findings will contribute to the elucidation of the molecular pathology of nephrolithiasis and the implementation of personalized medical care for this disease. 
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